Growth Differentiation Factor 15 in ICU Acquired Muscle Weakness

NCT06713746 | Completed DMC

• 1 other identifier: 7292021
• Study Type: observational
• Target: 58
• Locations: 1 country
• Sites: 1

Brief Summary

Intensive care unit -acquired weakness (ICU- AW) is a common consequence linked to a worse outcome as evidenced by prolonged mechanical ventilation, longer ICU stays, greater mortality rates and a lower quality of life for survivors, so early detection and treatment of ICU-AW are critical. However, there is no "gold standard" currently available for assessing and diagnosing ICU-AW. It's crucial to develop diagnostic methods that enable for early detection and risk stratification in all critically ill patients, such as: GDF-15 (growth differentiation factor-15) is thought to be a mediator of muscle atrophy because its level increases in the muscular atrophy As a result, measuring GDF-15 seems promise for diagnosing muscle atrophy.

Conditions

Muscle Weakness

Keywords

GDF15 Muscle weakness ICU

Outcome Measures

Primary Outcomes (2)

• Incidence

  to investigate the incidence of intensive care unit acquired muscle weakness

  1 year

• Disease relations

  to examine if there is any correlation between GDF15 level or urea-creatinine ratio and ICU acquired muscle weakness

  1 year

Secondary Outcomes (1)

• Daily activity and mortality

  1 year

Study Arms (1)

ICU patients

muscle weakness

Diagnostic Test: growth differentiation factor 15

Interventions

growth differentiation factor 15 DIAGNOSTIC_TEST

rowth differentiation factor-15 (GDF-15) is a novel cytokine secreted by a variety of cells like macrophages, adipocytes, normally expressed in high amounts by placenta

Also known as: urea to creatinine ratio

ICU patients

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients older than 18, conscious non mechanically ventilated patients and those with expected ICU stay more than 7 days during the period from September 2023 to September 2024

You may qualify if:

• age more than 18 conscious patients patients with expected ICU stay more than 7 days

You may not qualify if:

• \- unconscious patients spinal cord injury limb fracture or amputations history of cognitive dysfunction severe oedema end stage kidney disease

Sponsors & Collaborators

• Minia University: lead

Study Sites (1)

Minia university

Minya, Egypt

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood sample

MeSH Terms

Conditions

Muscle Weakness

Condition Hierarchy (Ancestors)

Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant lecturer of anesthesia and intensive care department

Study Record Dates

• First Submitted: November 29, 2021
• First Posted: December 3, 2024
• Study Start: September 10, 2023
• Primary Completion: September 10, 2024
• Study Completion: September 15, 2024
• Last Updated: December 9, 2024

Record last verified: 2024-11

Locations

EG (1)